De Novo KRAS G12C–Mutant SCLC: A Case Report

Meridith L. Balbach, BS; Rosana Eisenberg, MD; Wade T. Iams, MD

JTO Clinical and Research Reports (May 2022)

De Novo KRAS G12C–Mutant SCLC: A Case Report

Meridith L. Balbach, BS,
Rosana Eisenberg, MD,
Wade T. Iams, MD

Affiliations

Meridith L. Balbach, BS: Division of Hematology-Oncology, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee; Vanderbilt University School of Medicine, Nashville, Tennessee
Rosana Eisenberg, MD: Vanderbilt-Ingram Cancer Center, Nashville, Tennessee; Department of Pathology, Microbiology, and Immunology, Vanderbilt University Medical Center, Nashville, Tennessee
Wade T. Iams, MD: Division of Hematology-Oncology, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee; Vanderbilt-Ingram Cancer Center, Nashville, Tennessee; Corresponding author. Address for correspondence: Wade T. Iams, MD, Vanderbilt-Ingram Cancer Center, 2220 Pierce Avenue, 777 Preston Research Building, Nashville, Tennessee.

Journal volume & issue: Vol. 3, no. 5
p. 100306

Abstract

Read online

The application of KRAS G12C inhibitors in the setting of NSCLC represents a major milestone for a previously “undruggable” target. Here, we present the second reported case of de novo KRAS G12C–mutant primary SCLC. Would our patient benefit from a KRAS G12C inhibitor?

Published in JTO Clinical and Research Reports

ISSN: 2666-3643 (Online)
Publisher: Elsevier
Country of publisher: United States
LCC subjects: Medicine: Internal medicine: Neoplasms. Tumors. Oncology. Including cancer and carcinogens
Website: https://www.journals.elsevier.com/jto-clinical-and-research-reports/

About the journal

Abstract

Keywords